Pharma giants Sanofi SA and GlaxoSmithKline PLC (GSK) yesterday said that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine.
The agreement covers a vaccine candidate developed by France’s Sanofi in partnership with the UK’s GSK and is subject to a “final contract.”
Amid a race to find a vaccine to halt the pandemic, Sanofi announced “ongoing discussions with the European Commission, with France and Italy on the negotiation team, and other governments to ensure global access to a novel coronavirus vaccine.”
Photo: AFP
Both companies voiced in a statement their commitment “to making their COVID-19 vaccine candidate affordable and available globally.”
The vaccine candidate “has the potential to play a significant role in overcoming the COVID-19 pandemic, both in the UK and around the world,” GSK Vaccines president Roger Connor said.
Sanofi predicted regulatory approval for the vaccine “could be achieved by the first half of 2021.”
British Secretary of State for Business, Energy and Industrial Strategy Alok Sharma, quoted in the statement, hailed the progress, but said that “the fact remains that there are no guarantees.”
“In the meantime, it is important that we secure early access to a diverse range of promising vaccine candidates, like GSK and Sanofi, to increase our chances of finding one that works so we can protect the public and save lives,” Sharma said.
Britain has already secured access to 90 million doses of potential coronavirus vaccines in deals with biotech firms BioNTech SE, Pfizer Inc and Valneva SE.
The deals involve 30 million doses of a vaccine being developed by US pharma giant Pfizer and Germany’s BioNTech, and 60 million doses of another created by France’s Valneva.
The government in London has also said that it would purchase 100 million doses of a vaccine being trialed by the University of Oxford in partnership with AstraZeneca PLC.
“This diversity of vaccine types is important because we do not yet know which, if any, of the different types of vaccine will prove to generate a safe and protective response to COVID-19,” Kate Bingham, chairwoman of the British government’s vaccine task force, was quoted as saying.
Semiconductor business between Taiwan and the US is a “win-win” model for both sides given the high level of complementarity, the government said yesterday responding to tariff threats from US President Donald Trump. Home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), Taiwan is a key link in the global technology supply chain for companies such as Apple Inc and Nvidia Corp. Trump said on Monday he plans to impose tariffs on imported chips, pharmaceuticals and steel in an effort to get the producers to make them in the US. “Taiwan and the US semiconductor and other technology industries
SMALL AND EFFICIENT: The Chinese AI app’s initial success has spurred worries in the US that its tech giants’ massive AI spending needs re-evaluation, a market strategist said Chinese artificial intelligence (AI) start-up DeepSeek’s (深度求索) eponymous AI assistant rocketed to the top of Apple Inc’s iPhone download charts, stirring doubts in Silicon Valley about the strength of the US’ technological dominance. The app’s underlying AI model is widely seen as competitive with OpenAI and Meta Platforms Inc’s latest. Its claim that it cost much less to train and develop triggered share moves across Asia’s supply chain. Chinese tech firms linked to DeepSeek, such as Iflytek Co (科大訊飛), surged yesterday, while chipmaking tool makers like Advantest Corp slumped on the potential threat to demand for Nvidia Corp’s AI accelerators. US stock
The US Federal Reserve is expected to announce a pause in rate cuts on Wednesday, as policymakers look to continue tackling inflation under close and vocal scrutiny from US President Donald Trump. The Fed cut its key lending rate by a full percentage point in the final four months of last year and indicated it would move more cautiously going forward amid an uptick in inflation away from its long-term target of 2 percent. “I think they will do nothing, and I think they should do nothing,” Federal Reserve Bank of St Louis former president Jim Bullard said. “I think the
Cryptocurrencies gave a lukewarm reception to US President Donald Trump’s first policy moves on digital assets, notching small gains after he commissioned a report on regulation and a crypto reserve. Bitcoin has been broadly steady since Trump took office on Monday and was trading at about US$105,000 yesterday as some of the euphoria around a hoped-for revolution in cryptocurrency regulation ebbed. Smaller cryptocurrency ether has likewise had a fairly steady week, although was up 5 percent in the Asia day to US$3,420. Bitcoin had been one of the most spectacular “Trump trades” in financial markets, gaining 50 percent to break above US$100,000 and